8-K: Pasithea Therapeutics Secures $5 Million in Private Placement Priced At-The-Market

Pasithea Therapeutics has announced a $5 million private placement of common stock and warrants, priced at-the-market under Nasdaq rules, to fund working capital and general corporate purposes.

Summary

• Pasithea Therapeutics has entered into agreements for a private placement to raise approximately $5 million.
• The offering includes 1,219,513 shares of common stock (or pre-funded warrants), Series A warrants, and short-term Series B warrants.
• The purchase price is $4.10 per share or pre-funded warrant, with warrant exercise prices at $3.85 per share.
• Series A warrants expire five years from issuance, and Series B warrants expire in 18 months.
• The private placement is expected to close around September 30, 2024.
• H.C. Wainwright & Co. is the exclusive placement agent.
• Net proceeds will be used for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is raising capital, which is generally positive, the dilution of existing shareholders and the potential for further dilution from warrant exercises temper the overall sentiment. The use of proceeds for working capital is a standard practice.

Positives

• The private placement provides Pasithea with additional capital for working capital and general corporate purposes.
• The at-the-market pricing structure is beneficial for the company.
• The inclusion of warrants may attract investors.

Negatives

• The offering will dilute existing shareholders.
• The exercise price of the warrants is below the purchase price of the shares, which could lead to further dilution if exercised.
• The company will incur placement agent fees and other offering expenses.

Risks

• The closing of the offering is subject to customary closing conditions, which may not be met.
• The company's use of proceeds may not be as effective as anticipated.
• The company's clinical trials may not be successful.
• The company's future financial performance is subject to various risks and uncertainties.

Future Outlook

Pasithea intends to use the net proceeds from the offering for working capital and other general corporate purposes, and the company is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS).

Management Comments

• Pasithea is a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications.

Industry Context

This private placement is a common method for biotechnology companies to raise capital for research and development, especially for clinical-stage companies like Pasithea. The at-the-market pricing structure is a common approach for companies to raise capital without significantly impacting the market price of their stock.

Comparison to Industry Standards

• The structure of this private placement, including the use of common stock, pre-funded warrants, and accompanying warrants, is typical for biotech companies raising capital.
• The warrant exercise prices are set at a discount to the purchase price of the shares, which is a common incentive for investors.
• The use of H.C. Wainwright & Co. as the exclusive placement agent is consistent with industry practice for biotech companies seeking to raise capital.
• The stated use of proceeds for working capital and general corporate purposes is standard for companies in this sector.

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of new shares.
• Investors in the private placement will gain ownership in the company.
• The company will have additional capital to fund its operations and research.

Next Steps

• The private placement is expected to close on or about September 30, 2024.
• The company will file a resale registration statement covering the securities.
• Pasithea will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

private placement, common stock, warrants, biotechnology, financing, at-the-market, capital raise, neurofibromatosis, oncology, clinical stage